

Redefining Treatment for Neurodevelopmental Disorders

Corporate Overview



Dr Anthony Filippis
Chief Executive Officer & Managing Director

March 2026 | ASX: NTI



Forward-Looking Statements

This presentation includes forward looking statements. Forward looking statements can generally be identified by the use of the words “anticipate”, “believe”, “expect”, “project”, “forecast”, “estimate”, “likely”, “intend”, “should”, “could”, “may”, “target”, “plan” “guidance” and other similar expressions. Indications of, and guidance on, future earning or dividends and financial position and performance are also forward-looking statements.

Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All statements contained in this presentation, other than statements of historical fact, including without limitation statements regarding our strategy, research and development plans, collaborations, future operations, future financial position, future revenues, projected costs, pricing, prospects, plans, and objectives of management, are forward-looking statements. Not all forward-looking statements in this presentation are explicitly identified as such.


The Company does not warrant any of the forward-looking statements in this presentation, and investors are advised to interpret such statements in the context of other available sources of information and with the assistance of expert advisors as appropriate.

Many factors could cause the actual results of the Company to differ materially from the results expressed or implied herein, and you should not place undue reliance on the forward-looking statements. Drug development is inherently risky, and only a small proportion of research and development programs lead to a marketed product. Factors which could change the Company’s expected outcomes include, without limitation, our ability to: advance the development of our programs, and to do so within any timelines that may be indicated herein; the safety and efficacy of our drug development candidates; our ability to replicate experimental data; the ongoing validity of patents covering our drug development candidates, and our freedom to operate under third party intellectual property; our ability to obtain necessary regulatory approvals; our ability to enter into and maintain partnerships, collaborations, and other business relationships necessary to the progression of our drug development candidates; changes in the competitive landscape pertaining to our drug development candidates; the timely availability of necessary capital to pursue our business objectives; changes in the public policy environment in one or more countries in which we operate or may seek to operate which disfavour our business; our ability to attract and retain qualified personnel; changes from anticipated levels of customer acceptance of existing and new products and services; and other factors, including the COVID-19 pandemic and the conflict in Ukraine.

Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, and although they reflect our current views as at the date of this presentation, there can therefore be no assurance that such expectations will prove to be correct. The Company has no obligation as a result of this presentation to pursue any specific strategy or plan outlined herein, or to deliver any specific outcome that may be implied or inferred.

Any forward-looking statements contained in this presentation speak only as of the date this presentation is made, and we expressly disclaim any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

Neurotech: a high value investment opportunity



Neurotech is an ASX-listed (ASX: NTI) clinical-stage biotech company

Market cap of ~\$18m and cash at 31 Dec 2025 of \$6.3m

Phase 3 clinical trial program in autism spectrum disorder (ASD)

Placement to raise ~\$4m in Dec 2025

R&D Tax rebate \$4.73m in Nov 2025



Neurotech is developing NTI164 as a novel therapy for childhood neurological and neurodevelopmental disorders (NDD)

NTI164 targets neuroinflammation

It modulates microglia (the immune cells of the brain) to dampen their overactive inflammatory state in NDD

Data published in peer-reviewed scientific journals

Demonstrated clinical safety and efficacy in ASD, Rett syndrome and PANS



With four completed clinical trials across three indications, NTI164 moves into a Phase 3 clinical trial in ASD

Orphan drug and rare pediatric disease designations granted by US FDA and European EMA

Competitive landscape not crowded with few approved therapies in our target indications

Progressing global regulatory plans and partnering discussions

Targeting areas of significant unmet medical need. Epidiolex selling ~\$1b per year for two forms of epilepsy^[1]

^[1] [Jazz Pharmaceuticals full year 2025 financial results](#)

Targeting high impact indications where there is a clear unmet market need



autism spectrum disorder (ASD)

- 1 in 31 children (US)
- Boys 4x more likely to be diagnosed
- Global ~62M^[1]

- High unmet need for safe, effective treatments for core symptoms
- Current market ~US\$3B^[2] and growing
- Growing recognition by regulators



Rett syndrome

- Rare disease ~1 in 10,000-15,000 girls
- ~6,000-9,000 in US alone
- Global ~350,000^[3]

- High value orphan indication
- One FDA-approved drug (Daybue) with US\$375k/year pricing^[4]
- Net product sales US\$348M^[5]
- Accelerated regulatory pathways



PANS/PANDAS

- Emerging diagnosis
- ~1 in 200 in US alone^[6]
- Global cases not well defined

- No approved treatments
- Often misdiagnosed; high severity and family impact
- Fast-track potential if recognised

^[1] [The global epidemiology and health burden of the autism spectrum: findings from the Global Burden of Disease Study 2021](#)

^[2] [Research and Markets Autism Spectrum Disorders Market Report 2025](#)


^[3] [Rett Syndrome: Crossing the Threshold to Clinical Translation](#)

^[4] [Neuren Pharmaceuticals 2022 Annual Report](#)

^[5] [Acadia Pharmaceuticals Full Year 2024 financial results 26 Feb 2025](#)

^[6] [PANDAS network](#)

Neurotech's pipeline comprises clinical programs in neurodevelopmental disorders of children where neuroinflammation is involved



What is NTI164?

1 Disease-modifying transformative therapy in neurodevelopmental disorders

2 Standardised, pharma-grade CNS modulator, targeting neuroinflammation

3 Multi-small molecule profile with CBDA dominance, pharma-grade oil

4 Orally administered, Twice daily, 5mg/kg/day



7 Safe and effective in non-clinical and clinical studies; backed by clinical data and open to partnering opportunities

6 Patent applications cover composition of matter, methods of use and formulations

5 Unique anti-inflammatory, neuroprotective, and epigenetic effects

NTI164 – Clinical Data Demonstrated Improvements

Across three clinical studies in Autism and Rett syndrome, NTI164 consistently improved the outcomes that matter most to families.

THE FOUR PILLARS OF CHANGE

Phase II/III HARMONY Autism Spectrum Disorder Clinical Trial

GLOBAL SYMPTOM SEVERITY

84%

of patients showed improvement within the first 8 weeks of NTI164 treatment

- Children moved down in illness severity ratings.
- Clinicians rated clinically meaningful overall improvement.

Measured by the Clinical Global Impression of Improvement (CGI-I) scale

COMMUNICATION & COGNITIVE ENGAGEMENT

- Better engagement.
- More alertness.
- More expressive behaviour.

Measured by the Vineland-3

+3.23

in the Vineland-3 - a meaningful improvement in communication ability

-3.064

reduction in social challenges – a meaningful improvement in social responsiveness

SOCIAL ENGAGEMENT

- Improved social responsiveness and interaction.
- Greater engagement with caregivers.

Measured by the SRS-2

ANXIETY REDUCTION

- Reduced anxiety.
- Improved mood regulation.
- Fewer behavioural disturbances.


Measured by the ADAMS scale

39%

improvement in anxiety scores

When communication improves, anxiety decreases, and families feel relief – that is significance.

Approval for Phase III BEYOND HARMONY clinical trial in ASD



*Adaptive design

ASD Phase III roadmap and value inflection points



Phase III program supported by clinical data:

- Statistically significant and clinically meaningful Phase II/III efficacy signals
- Consistent safety profile across prior clinical exposure
- TGA/FDA-aligned registration endpoints
- Large unmet market need – no approved therapies for core ASD symptoms
- Scalable, commercially viable formulation
- Partnering discussions with pharmaceutical and biotechnology companies ongoing

Note: The above roadmap is a statement of current intentions as at the date of this presentation. Intervening events may alter the timing, sequence or feasibility of the matters described. Accordingly, there can be no assurance that the milestones outlined will be achieved within the anticipated timeframes, or at all.

NTI164 – Clinical Data Demonstrated Improvements

Across three clinical studies in Autism and Rett syndrome, NTI164 consistently improved the outcomes that matter most to families.

THE FOUR PILLARS OF CHANGE

Phase I/II Rett Syndrome Clinical Trial

GLOBAL SYMPTOM SEVERITY

93%

showed overall clinical improvement

- Children moved down in illness severity ratings.
- Clinicians rated clinically meaningful overall improvement.

Measured by the Clinical Global Impression scales

86%

showed improvement in social interaction or eye contact

Measured by the Socialisation/Eye-contact CGI-I sub-domains

SOCIAL ENGAGEMENT

- Improved social responsiveness and interaction.
- Greater engagement with caregivers.

COMMUNICATION & COGNITIVE ENGAGEMENT

-10.53

point reduction in communication and cognitive engagement difficulties

Measured by the RSBQ subdomains

ANXIETY REDUCTION

- Reduced anxiety.
- Improved mood regulation.
- Fewer behavioural disturbances.

Measured by Anxiety and Mood sub-domains in Rett trial

56%

showed reduction in anxiety-related behaviours

US EU
Granted Orphan Drug Designation

US
Granted Rare Pediatric Disease Designation


When communication improves, anxiety decreases, and families feel relief – that is significance.

Rare paediatric disease Priority Review Voucher re-instated

Priority Review Voucher Program

- The Rare Pediatric Disease Priority Review Voucher (PRV) program sunset on 20 December 2024, causing a period of uncertainty for rare disease drug developers
- Companies could still apply for Rare Pediatric Disease Designation (RPDD) and sell previously obtained PRV
- RPDD is one of the eligibility requirements that must be satisfied before a sponsor may be eligible to receive a PRV following FDA approval of a qualifying product.
- Other key eligibility requirements to obtain a PRV include:
 - FDA approval of a New Drug Application (NDA) or Biologics License Application (BLA)
 - The drug must contain a new active ingredient not previously approved
- NTI164 obtained RPDD for Rett syndrome in October 2025
- On 3 February 2026, the Rare Pediatric Disease PRV program was re-instated
- Established in 2012, 63 Rare Pediatric Disease PRV have been awarded across 47 rare diseases^[4]
- Publicly reported Priority Review Voucher transaction prices over time are illustrated in the chart.

Priority Review Voucher Open Market Sales



Source: FDA, Federal Register, Company Reports, SEC, GAO • Chart by Annalee Armstrong/BioSpace

The above chart illustrates publicly reported historical Priority Review Voucher transaction prices based on available market data. For details, refer to: <https://www.biospace.com/business/priority-review-vouchers-by-the-numbers>

^[4] Impact of the Rare Pediatric Disease Priority Review Voucher Program on Drug Development From 2012–2025 <https://rarediseases.org/wp-content/uploads/2025/08/NRD-2342-PRV-Policy-Report-November-2025.pdf>

While there is no assurance that NTI164 will obtain PRV, Neurotech notes that obtaining RPDD is part of the eligibility criteria an applicant for PRV must first satisfy. If eligible, Neurotech intends to seek a PRV in connection with NTI164, subject to FDA approval of a qualifying product and satisfaction of all applicable eligibility requirements. Neurotech also notes that the price of PRV is subject to consistent fluctuation and there is no guarantee that a specific price could be obtained by Neurotech in the event it obtained a PRV.























Authorised Prescribers (AP) Scheme: Enabling NTI164 demand

Authorised Prescribers Scheme

The Authorised Prescriber Scheme allows authorised medical practitioners to prescribe medicines, medical devices or biologicals that are not included in the Australian Register of Therapeutic Goods to a class of patients with a particular medical condition.

- Enabling NTI164 demand
 - Rationale for AP scheme was due to patient/family demand for NTI164
 - Scalable access provided through NTI-selected Australian registered medical practitioners (Authorised Prescribers) who can prescribe NTI164 to multiple patients in a supervised environment
- Generate real-world evidence
 - Patients gain access once an AP scheme is in place, accelerating uptake across key indications
 - Real-world data through the AP scheme generates valuable safety and effectiveness data to strengthen regulatory, partnering, advocacy and payer discussions
- Part of broader commercial access strategy
 - Establishes early adoption and market presence for NTI164 ahead of pivotal trials and potential registration
 - Commercial access and registration strategy

The competitive landscape is not crowded with few approved therapies

| | Early Development | Late Development | Approved |
|---|---|--|---|
| Autism Spectrum Disorder <i>Several off-label use of other neuropsychiatric drugs which have side effects</i> |     |  NTI164      |     |
| Rett Syndrome <i>Only a few Phase I/II clinical trials underway, with late development failure</i> |  NTI164   |  Blarcamesine |   |
| PANDAS/PANS <i>Emerging area, strong patient advocacy</i> |  NTI164 |  Panzyga | No approved drugs |

Risperdal firstly developed by Janssen-Cilag & Ablify by Otsuka

Originally approved for Schizophrenia, now used for irritability and aggression in children > 5-6 yrs with ASD

Daybue, the first treatment approved in Rett Syndrome. 61% of patients showed no improvement, with no data on which symptoms improve. Costs ~US\$375K, selling US\$348M* in 2024

In Jan 2024, Blarcamesine failed to meet primary endpoint in Phase II/III clinical trial











Antibiotics commonly used. IVIG (Panzyga) approved for other indications shown to ease symptoms

Neurotech ahead of the curve in recognising this devastating disorder

Not exhaustive list, NTI internal analysis, BioKnow ASD landscape Feb 2025

*Acadia Pharmaceuticals Full Year 2024 financial results 26 Feb 2025


Market comparators provide a strong precedent for NTI164

| Market comparators | | |
|--|--|-------------|
| Company | Comparable pipeline | Market Cap |
|  Jazz Pharmaceuticals |  Epidiolex [®] (cannabidiol, approved) | ~ US\$10.3B |
|  ACADIA |  Daybue [™] (trofinetide) (approved) | ~ US\$4.1B |
|  neuren pharmaceuticals | NNZ-2591 Phase 2 data including Angelman, Phelan McDermid, Pitt Hopkins | ~AU\$1.7B |
|  anavex LIFE SCIENCES Corp | Anavex 2-73 (Blarcamesine) Phase 2/3 for Rett Syndrome (failed Jan 2024) Phase 2/3 for ASD | ~US\$376M |
|  HARMONY BIOSCIENCES | Zyn-002 (cannabidiol gel) Phase 3 for Fragile X Syndrome (failed Sep 2025) Phase 3 for epilepsy | ~US\$1.9B |
|  Taysha GENE THERAPIES | Gene therapies for monogenic CNS diseases Phase 1/2 for Rett Syndrome | ~US\$1.3B |
|  NEUROGENE | Phase 1/2 for Rett Syndrome Phase 1/2 for Batten Disease | ~US\$285M |
|  Neurotech International | Phase 2/3 data in ASD Phase 1/2 data in Rett Syndrome Phase 1/2 data in PANDAS/PANS | ~AU\$18M |

Neurotech is moving forward with a Phase 3 clinical trial in ASD and is valued at ~AU\$18M

The company has commenced a broad outreach program to socialise and nurture potential future partners for NTI164

Typical Structure of Pharma Partnering Transactions






















Benchmarks for Phase II/III Neuro Disease Partnering Transactions (2016 – 2025 YTD) (n=64)

| | Low | Median | High |
|-----------------------------|-----|--------|-------|
| Upfront Cash/Equity (US\$M) | 3 | 40 | 1000 |
| Milestones (US\$M) | 120 | 467 | 1,900 |
| Royalties | 5% | 9% | 12% |

The capability and commitment of a partner to develop and commercialise the product can be as crucial as the financial terms of the transaction

Partnering opportunity for NTI164 is substantial, with benchmark transactions suggesting significant value potential

| Licensing Transactions | | | | | | |
|---|---|-----------------------------|----------------------------------|----------|----------|-------------------|
| Licensee | Licensor | Key Asset(s) | Key Indication(s) | Stage | Date | Deal Value (US\$) |
|  NOVARTIS |  PTC THERAPEUTICS | PTC518 | Huntington's disease | Phase II | Nov 2024 | \$2.9B |
|  ABVC BIOPHARMA |  AI BTL BIOPHARMA | ABV-1504/1505 | ADHD, depression | Phase II | Nov 2023 | \$667M |
|  ACADIA |  neuren pharmaceuticals | Trofinetide (xUS), NNZ-2591 | Rett syndrome (ex-US) | Phase II | Jul 2023 | \$931M |
|  sanofi | MAZE THERAPEUTICS | MZE-001 | Pompe disease | Phase I | May 2023 | \$750M |
|  ACADIA |  saniona | SAN711 | Essential tremor | Phase I | Nov 2024 | \$582M |
|  NS Pharma |  Capricor THERAPEUTICS | CAP-1002 (United States) | Duchenne muscular dystrophy | Phase II | Jan 2022 | \$735M |
|  STALICLA |  NOVARTIS | Mavoglurant | Autism, mood disorders | Phase II | Jan 2023 | \$270M |
| M&A Transactions | | | | | | |
| Acquirer | Target | Key Asset(s) | Key Indication(s) | Stage | Date | Deal Value (US\$) |
|  Pfizer |  ARENA PHARMACEUTICALS | Olorinab (cannabinoid) | Immuno-inflammatory disorders | Phase II | Dec 2021 | \$6.7B |
|  Jazz Pharmaceuticals |  GW pharmaceuticals | Epidiolex (cannabinoid) | Dravet, Lennox Gastaut syndromes | Approved | Feb 2021 | \$7.2B |
|  Biogen |  REATA PHARMACEUTICALS | Skyclarus | FA, neurological disorders | Approved | Jul 2023 | \$7.3B |

Source: Non-exhaustive list, DealForma, company press releases, Neurotech research

Bringing botanical medicines to market: it can be done

| FDA-approved botanical prescription drugs | | | | | |
|---|----------------------|--|---|--------------|---|
| Drug name | Active ingredient(s) | Botanical source | Indication(s) | FDA approval | Notes |
| Veregen® | Sinecatechins | <i>Camellia sinensis</i> (green tea) | Genital & perianal warts (HPV) | 2006 | First FDA approved botanical ointment; standardised polyphenol mixture ^[1] |
| Fulyzaq®/Mytesi® | Crofelemer | <i>Croton lecheri</i> (dragon's blood) | Non-infectious diarrhea in HIV/AIDS | 2012 | Rebranded as Mytesi® for chronic diarrhea management ^[1] |
| Epidiolex® | Cannabidiol (CBD) | <i>Cannabis sativa</i> (hemp) | Epilepsy (Lennox-Gastaut, Dravet syndromes) | 2018 | First FDA-approved cannabis-derived drug ^[2] |

| Several FDA-approved prescription drugs derived from plants | | | | | |
|---|----------------------|--|-------------------------------|--------------|---|
| Drug name | Active ingredient(s) | Botanical source | Indication(s) | FDA approval | Notes |
| Taxol® | Paclitaxel | <i>Taxus brevifolia</i> (Pacific yew bark) | Breast, ovarian, lung cancer | 1992 | Blockbuster oncology drug, peak annual sales ~US\$1.6B ^[3] |
| Taxotere® | Crofelemer | Semi-synthetic from Paclitaxel precursor | Breast, prostate, lung cancer | 1996 | Successor to Taxol® |

^[1] U.S. Food and Drug Administration (2015). *Botanical Drug Review: Overview of FDA's Botanical Drug Development Program*. Presentation by Office of New Drugs, Center for Drug Evaluation and Research. Presented November 17, 2015.

^[2] U.S. Food and Drug Administration (2018). *Drug Trials Snapshots: Epidiolex*. FDA Drug Trials Snapshot Series. Published 2018.

^[3] Chemical & Engineering News (2000). Paclitaxel sales peaked at nearly \$1.6 billion in 2000.

Neurotech Board and management bring extensive international experience in drug development, finance and commercialisation



Mr Mark Davies
Board Chair

Over 25 years experience in trading, finance, investment banking and providing corporate advice



Dr Anthony Filippis
Managing Director & CEO

Over 25 years of life sciences leadership experience, with a focus on BD, corporate strategy, and operations



Mr Max Johnston
Non-Executive Director

Over 40 years pharma leadership. Over 10 years as Chief Executive Officer of Johnson and Johnson Pacific. Sits on several ASX listed Boards



Dr Bonni Goldstein
Chief Medical Advisor

Over 25 years of clinical experience including 17 years exclusively on cannabinoid therapies



Mr Gerald Quigley
Non-Executive Director

Qualified Pharmacist. Leading media health commentator heard each week on television and radio stations across Australia



Neurotech financial position and value drivers

Corporate Fundamentals

| | |
|------------------------|--------------|
| Market Capitalisation: | ~AU\$ 18.2M |
| Primary Listing: | ASX: NTI |
| Shares on Issue: | 1.30 Billion |

Cash Position

| | |
|---------------------------|-----------------|
| Cash Balance (31 Dec 25): | AU\$6.3 Million |
|---------------------------|-----------------|

Shareholders

| | |
|--------------------|--------|
| Top 40 (31 Jan 26) | 54.01% |
|--------------------|--------|

Analyst Coverage



Huge Market Potential

Addressing high-growth neurological markets

Proven science and de-risked programs

Positive clinical results supporting efficacy & safety



Clear Commercial Pathway

Strong IP, regulatory and commercial path

Strong Leadership & Vision

Experienced team driving execution

Value-driving catalysts on the horizon

| CY2026 | | |
|--|-------------|---|
| Human Research Ethics Committee approval for ASD registration-enabling study | 1Q CY2026 |  |
| Initiation of first clinical site | 1Q CY2026 |  |
| First patient enrolled in ASD clinical trial | Mid CY2026 | |
| Long-term chronic toxicology data | Mid CY2026 | |
| IND submission for ASD | 1H CY2026 | |
| IND submission Rett syndrome | 1H CY2026 | |
| ASD registration-enabling data readout | Late CY2026 | |

Note: The above roadmap is a statement of current intentions as at the date of this presentation. Intervening events may alter the timing, sequence or feasibility of the matters described. Accordingly, there can be no assurance that the milestones outlined will be achieved within the anticipated timeframes, or at all.



Thank You & Contact Details



Neurotech Investor Relations:

info@neurotechinternational.com

www.neurotechinternational.com



This presentation was approved for release by the Board

